Chemical Papers
cytotoxity with LC50 <100 µg/mL. The products exhibited
much higher cytotoxic activity than the 16-arylidene ster-
oids, which indicated that the introduction of the phenyl spi-
ropyrrolidene indeno quinoxaline signifcantly improved the
cytotoxic efect of the steroidal derivatives. 11H-indeno[1,2-
b]quinoxalin-11-one exhibited moderate cytotoxity with a
LC50 of 72.05 µg/mL which is stronger than other raw mate-
rials. The presence of indeno quinoxaline moiety contributed
to the cytotoxic activity of the steroidal spiro-heterocyclic
products to a certain extent.
Experimental
Materials
Fig. 3 ORTEP diagram of 3c (all H atoms have been omitted)
All the chemical reagents were commercially available and
used without further purifcation. All the solvents were dried
and redistilled before use. The thin-layer chromatography
(TLC) analysis was performed with silica gel GF254 plates.
The column chromatography was carried out using silica
gel (200–300 mesh). All NMR spectra were recorded on
a Bruker AV-II 500 MHz NMR spectrometer, operating
Taking products out of the reaction system or adding the
cheap reactant is an efective way to improve the conver-
sion rate of the substrate in equilibrium reaction. The equi-
librium shift of the [3+2] cycloaddition reaction between
16-(4-methoxyphenylmethylene) dehydroepiandrosterone
(1f) and the azomethine ylide from 11H-indeno[1,2-b]qui-
noxalin-11-one and sarcosine was studied (SI Part B). At
the beginning, the poor solubility of the product 3f leaded to
its low concentration in acetonitrile solution. As monitored
by UPLC-PDA-ESIMS, the reaction equilibrium tends to
form cycloaddition product 3f. But the change of the reac-
tion system will not be obvious when the concentration of
reactants dropped to a lower level after 15 h and the system
reached equilibrium in the solution. By adding sarcosine,
the reaction continues to aford the product smoothly until
the system reached another equilibrium at the 25th hour.
Then the conversion rate of reaction substrate is maintained
at a constant level, and 3f was obtained by fltration with a
moderate yield (55%) after 30 h.
1
at 500 MHz for H, and 126 MHz for 13C. TMS was used
as an internal reference for 1H and 13C chemical shifts and
CDCl3 was used as solvent. All the mass spectra and reac-
tion system monitoring data were obtained using a Waters
ACQUITY UPLC equipped a PDA detector and a successive
XEVO Q-TOF mass spectrometer. IR spectra were recorded
on a PerkinElmer spectrometer. Melting points were meas-
ured with a Yanaco MP500 melting point apparatus and
are uncorrected. The crystallographic data for compound
3c are summarized in the Table S1 in Supporting Informa-
tion. CCDC 1953655 contains the supplementary crystal-
lographic data, which can be obtained free of charge from
Bioassay
Chemicals
All the starting materials including dehydroepian-
drosterone, 16-arylidene dehydroepiandrosterones
(1a–1g), 11H-indeno[1,2-b]quinoxalin-11-one (2), and
sarcosine, along with the synthesized 1′-N-methyl-
spiro[2′,11″]-indeno[1,2-b]quinoxaline-spiro[3′,16]-
dehydroepiandrosterone-4′-arylpyrrolidines (3a–3g) were
(Meyer et al. 1982). The products showed cytotoxic efects
27.2 µg/mL. Compound 3d and 3g had the most signifcant
cytotoxic bioactivities with LC50 values of 6.19 and 9.92 µg/
mL, respectively. The dehydroepiandrosterone, 16-arylidene
dehydroepiandrosterones and sarcosine did not show
Typical procedure for the synthesis of 16‑arylidene
dehydroepiandrosterones (1a–1g)
The mixture of dehydroepiandrosterone (500 mg,
1.73 mmol) and 4-methylthio-benzaldehyde (263.9 mg,
1.73 mmol) was dissolved in EtOH (20 mL). The reaction
solution was refuxed about 2 h after addition of 2 mL aque-
ous NaOH solution (NaOH, 346.7 mg, 8.67 mmol), and the
reaction progress was monitored by TLC. Then the reaction
mixture was fltrated to give a pale yellow solid after being
slowly cooled to room temperature. The solid was washed
with 50% aqueous EtOH solution and dried to give pure
1a (670 mg, 94%). The synthesis and separation of other
1 3